Trials / Completed
CompletedNCT02003534
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 376 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.15% Brimonidine Tartrate | 0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2013-12-06
- Last updated
- 2014-07-22
- Results posted
- 2014-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02003534. Inclusion in this directory is not an endorsement.